Literature DB >> 1472463

Cortisol metabolism by human liver in vitro--I. Metabolite identification and inter-individual variability.

S M Abel1, J L Maggs, D J Back, B K Park.   

Abstract

The measurement of urinary 6 beta-hydroxycortisol (6 beta-OHF) has been widely used as a non-invasive clinical test to detect cytochrome P450 induction. Although only a minor biotransformation, 6 beta-OHF formation represents a sensitive target for many P450-inducing drugs and environmental chemicals in man. There is good evidence that an isozyme of the P450IIIA subfamily is predominantly responsible for 6 beta-hydroxylase activity and therefore it has been suggested that urinary 6 beta-OHF is a marker of the induction of P450IIIA. The basis of the present study was that in order to realistically assign to 6 beta-OHF the status of a P450IIIA marker we should characterize all the metabolites of cortisol produced by human liver and assess inter-liver variability. Incubations at 37 degrees C for 2 h contained [3H]cortisol (0.1 microCi, 1 or 50 microM), MgCl2 (10 mM), microsomal or cytosolic protein (3 mg), an NADPH-regenerating system and 1/15 M phosphate buffer (pH 7.4) to give a final volume of 0.5 ml. Extraction with ethyl acetate (2 x 2 ml) was followed by radiometric HPLC analysis. Metabolites were identified by co-chromatography with authentic standards and mass spectrometry (electron impact and chemical ionization). All the microsomal incubations (n = 6 livers) produced 6 alpha-hydroxycortisol (6 alpha-OHF), 6 beta-OHF, 20 beta-dihydroxycortisol, 20 beta-dihydroxycortisone, cortisone, and 3 alpha, 5 beta-tetrahydrocortisone (3 alpha, 5 beta-THE), while five produced 6 beta-hydroxycortisone and four produced 3 alpha, 5 beta-tetrahydrocortisol (3 alpha, 5 beta-THF). The cytosolic incubations gave a much simpler metabolic profile, with 3 alpha, 5 beta-THF the major metabolite and 3 alpha, 5 beta-THE a minor metabolite. There was considerable inter-individual variability in metabolite profiles from microsomal incubations. 6 beta-OHF varied from 2.8 to 31.7%. Major metabolites were cortisone and 3 alpha, 5 beta-THE. Inter-liver variability was less for cytosolic incubations, the major metabolite always being 3 alpha, 5 beta-THF. In conclusion we have rigorously identified the hepatic metabolites of cortisol formed in vitro. The highly complex and variable hepatic metabolism of cortisol clearly limits the use of urinary 6 beta-OHF excretion as a marker of baseline P450IIIA activity in man.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1472463     DOI: 10.1016/0960-0760(92)90297-v

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  10 in total

1.  Activities of aldo-keto reductase 1 enzymes on two inhaled corticosteroids: implications for the pharmacological effects of inhaled corticosteroids.

Authors:  Yi Jin
Journal:  Chem Biol Interact       Date:  2011-01-27       Impact factor: 5.192

Review 2.  Phenotyping of Human CYP450 Enzymes by Endobiotics: Current Knowledge and Methodological Approaches.

Authors:  Gaëlle Magliocco; Aurélien Thomas; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

3.  Evaluation of 6β-hydroxycortisol, 6β-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo.

Authors:  C-C Peng; I Templeton; K E Thummel; C Davis; K L Kunze; N Isoherranen
Journal:  Clin Pharmacol Ther       Date:  2011-04-13       Impact factor: 6.875

4.  Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats.

Authors:  G M Ferron; N A Pyszczynski; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1999-02

5.  Proceedings of the British Pharmacological Society. Clinical Pharmacology Section. 14-16 April 1993. Abstracts.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1993-08       Impact factor: 4.335

6.  Canine urinary lactate and cortisol metabolites in hypercortisolism, nonadrenal disease, congestive heart failure, and health.

Authors:  Arnon Gal; Ryan Fries; Saki Kadotani; Alexander V Ulanov; Zhong Li; J Catharine Scott-Moncrieff; Richard K Burchell; Nicolas Lopez-Villalobos; Yigal Petreanu
Journal:  J Vet Diagn Invest       Date:  2022-06-03       Impact factor: 1.569

7.  Effect of the fluoroquinolone antibacterial agent DX-619 on the apparent formation and renal clearances of 6β-hydroxycortisol, an endogenous probe for CYP3A4 inhibition, in healthy subjects.

Authors:  Yuichiro Imamura; Nobuyuki Murayama; Noriko Okudaira; Atsushi Kurihara; Katsuhisa Inoue; Hiroaki Yuasa; Takashi Izumi; Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2012-10-17       Impact factor: 4.200

8.  Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism.

Authors:  Xi Luo; Xiao-min Li; Zhe-yi Hu; Ze-neng Cheng
Journal:  Acta Pharmacol Sin       Date:  2009-08-24       Impact factor: 6.150

Review 9.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

10.  Carbonyl reductase 1 catalyzes 20β-reduction of glucocorticoids, modulating receptor activation and metabolic complications of obesity.

Authors:  Ruth A Morgan; Katharina R Beck; Mark Nixon; Natalie Z M Homer; Andrew A Crawford; Diana Melchers; René Houtman; Onno C Meijer; Andreas Stomby; Anna J Anderson; Rita Upreti; Roland H Stimson; Tommy Olsson; Tom Michoel; Ariella Cohain; Arno Ruusalepp; Eric E Schadt; Johan L M Björkegren; Ruth Andrew; Christopher J Kenyon; Patrick W F Hadoke; Alex Odermatt; John A Keen; Brian R Walker
Journal:  Sci Rep       Date:  2017-09-06       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.